[Sipuleucel-T: a prostate cancer vaccine: "instructions for use" for urologists]. / Sipuleucel-T : un vaccin contre le cancer de la prostate : « mode d'emploi ¼ pour les urologues.
Prog Urol
; 21(9): 595-8, 2011 Oct.
Article
em Fr
| MEDLINE
| ID: mdl-21943654
ABSTRACT
Sipuleucel-T is the first approved vaccine for prostate cancer, opening the pathway for this new treatment approach. The treatment process consists in isolating the patient dentritic cells via leukapherisis, stimulate and infuse them into the patient. These enhanced cells are then able to stimulate patient T lymphocytes to target the tumour cells. The median survival in the pivotal study, IMPACT, as well as in the previously reported randomised trials, was 4.1 months longer in the sipuleucel-T group. The estimated probability of survival 36 months after randomisation was 31.7% in the sipuleucel-T group and 23.0% in the placebo group. However, the median time to objective disease progression was similar in the two groups (hazard ratio 0.95; 95% CI, 0.77 to 1.17; P=0.63). We report herein, the treatment modalities, side effects and results in the light of recently published randomised trials.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Extratos de Tecidos
/
Vacinas Anticâncer
Tipo de estudo:
Clinical_trials
Limite:
Humans
/
Male
Idioma:
Fr
Revista:
Prog Urol
Assunto da revista:
UROLOGIA
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
França